Indications -- Psoriasis/Chronic Inflammation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	4/22/2002 3:50:22 AM
From: nigel bates	of 631

Morphosys / CD54 Message 17363098 ...MorphoSys will present details of its first proprietary therapeutic antibody candidates, MOR101 and MOR102. Both antibodies were developed with the Company's HuCAL® technology and target ICAM-1 (intercellular adhesion molecule-1), also known as CD54. MOR101 will be developed for deep dermal burn. The drug, intended to be developed as a Fab fragment, is expected to meet a significant medical need, as there are currently no drugs in development or on the market, which treat the disease. MOR101 is expected to enter clinical trials in 2003. MOR102 is an IgG antibody, and will target psoriasis, and is anticipated to enter clinical trials in 2004. The psoriasis market is large, and there is substantial demand for improved treatments for the disease. The Company believes MOR102 possesses significant benefit over current approaches to the treatment of psoriasis due to its strong anti-inflammatory properties, and minimal immune suppressive effects. MOR101 and MOR102 may be developed in further indications in the future...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next